Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Wheler JJ"'
Autor:
Park, H, Garrido-Laguna, I, Naing, A, Fu, S, Falchook, GS, Piha-Paul, SA, Wheler, JJ, Hong, DS, Tsimberidou, AM, Subbiah, V, Zinner, RG, Kaseb, AO, Patel, S, Fanale, MA, Velez-Bravo, VM, Meric-Bernstam, F, Kurzrock, R, Janku, F
Publikováno v:
Oncotarget, vol 7, iss 41
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::512319f3ff14299dfb14919f0d8072de
https://escholarship.org/uc/item/1dp7g79p
https://escholarship.org/uc/item/1dp7g79p
Autor:
Ballhausen A; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Wheler JJ; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Pant S; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsimberidou AM; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Holley VR; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Huang HJ; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Brewster AM; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Koenig KB; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ibrahim NK; Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Janku F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Mar 01; Vol. 27 (5), pp. 1247-1255. Date of Electronic Publication: 2020 Oct 28.
Autor:
Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.
Autor:
Tsimberidou AM; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. atsimber@mdanderson.org., Hong DS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Wheler JJ; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: TScan Therapeutics, Waltham, USA., Falchook GS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Sarah Cannon Research Institute, Nashville, USA., Janku F; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Naing A; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Fu S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Piha-Paul S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Cartwright C; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Broaddus RR; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Nogueras Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kurzrock R; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Moores Cancer Center-University of California San Diego, San Diego, USA.
Publikováno v:
Journal of hematology & oncology [J Hematol Oncol] 2019 Dec 30; Vol. 12 (1), pp. 145. Date of Electronic Publication: 2019 Dec 30.
Autor:
Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, 520 Country Club Rd., Eugene, OR, 97401, USA. Jeff.Sharman@usoncology.com.; US Oncology Research, Houston, TX, USA. Jeff.Sharman@usoncology.com., Wheler JJ; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Einhorn L; Indiana University Division of Hematology and Oncology, 535 Barnhill Dr, Indianapolis, IN, 46202, USA., Dowlati A; Department of Medicine - Hematology and Oncology, University Hospitals Case Medical Center, 11100 Euclid Ave., Cleveland, OH, 44106, USA., Shapiro GI; Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA., Hilton J; Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada.; Ottawa Hospital Research Institute, 501 Smyth, Box 511, Ottawa, Ontario, K1H 8L6, Canada., Burke JM; US Oncology Research, Houston, TX, USA.; Rocky Mountain Cancer Centers, 1700 South Potomac St., Aurora, CO, 80012, USA., Siddiqi T; City of Hope National Medical Center, 1500 East Duarte Rd., Duarte, CA, 91010, USA., Whiting N; Seattle Genetics, Inc., 21823 30th Dr. SE, Bothell, WA, 98021, USA., Jalal SI; Indiana University Division of Hematology and Oncology, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2019 Aug; Vol. 37 (4), pp. 738-747. Date of Electronic Publication: 2019 Apr 16.
Autor:
Aghajanian C; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), 300 East 66th Street, New York, NY, 10065, USA. aghajanc@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. aghajanc@mskcc.org., Bell-McGuinn KM; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), 300 East 66th Street, New York, NY, 10065, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.; Eli Lilly and Company, Indianapolis, IN, USA., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN, USA.; Tennessee Oncology, Nashville, TN, USA., Siu LL; Princess Margaret Cancer Centre, Toronto, Canada., Stayner LA; Princess Margaret Cancer Centre, Toronto, Canada., Wheler JJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kurkjian C; Sarah Cannon Research Institute, Nashville, TN, USA.; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA., Pant S; Sarah Cannon Research Institute, Nashville, TN, USA.; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA., Santiago-Walker A; GlaxoSmithKline, Collegeville, PA, USA.; Janssen, Lansdale, PA, USA., Gauvin JL; GlaxoSmithKline, Collegeville, PA, USA.; Novartis Pharmaceuticals, Orlanda, Florida, USA., Antal JM; GlaxoSmithKline, Collegeville, PA, USA.; MedImmune, Gaithersburg, MD, USA., Opalinska JB; GlaxoSmithKline, Collegeville, PA, USA.; Boehringer-Ingelheim, Ridgefield, CT, USA., Morris SR; GlaxoSmithKline, Collegeville, PA, USA.; MedImmune, Gaithersburg, MD, USA., Infante JR; Sarah Cannon Research Institute, Nashville, TN, USA.; Tennessee Oncology, Nashville, TN, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2018 Dec; Vol. 36 (6), pp. 1016-1025. Date of Electronic Publication: 2018 Apr 03.
Autor:
Chawla A; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Wheler JJ; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Miller VA; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Ryan J; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Anhorn R; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Zhou Z; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX., Signorovitch J; , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2018 Nov 02; Vol. 2. Date of Electronic Publication: 2018 Nov 02 (Print Publication: 2018).
Autor:
Sakamuri D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Betancourt Cuellar SL; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sarah Cannon Research Institute at HealthONE, Denver, Colorado., Fanale MA; Department of Lymphoma and Myeloma Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cabanillas ME; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2018 Mar; Vol. 17 (3), pp. 671-676. Date of Electronic Publication: 2017 Dec 13.
Autor:
Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. drilona@mskcc.org., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Ou SI; Chao Family Comprehensive Cancer Center, University of California, Irvine, California., Patel M; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida., Ahn MJ; Samsung Medical Center, Seoul, Korea., Lee J; Samsung Medical Center, Seoul, Korea., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee., Farago AF; Massachusetts General Hospital, Boston, Massachusetts., Wheler JJ; The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC., Doebele R; University of Colorado Cancer Center, Aurora, Colorado., Giannetta L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Cerea G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Marrapese G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Schirru M; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bencardino K; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Palmeri L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Vanzulli A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Cresta S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Damian S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Duca M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ardini E; Nerviano Medical Sciences s.r.l, Milan, Italy., Li G; Ignyta, Inc., San Diego, California., Christiansen J; Ignyta, Inc., San Diego, California., Kowalski K; Ignyta, Inc., San Diego, California., Johnson AD; Ignyta, Inc., San Diego, California., Patel R; Ignyta, Inc., San Diego, California., Luo D; Ignyta, Inc., San Diego, California., Chow-Maneval E; Ignyta, Inc., San Diego, California., Hornby Z; Ignyta, Inc., San Diego, California., Multani PS; Ignyta, Inc., San Diego, California., Shaw AT; Massachusetts General Hospital, Boston, Massachusetts., De Braud FG; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Cancer discovery [Cancer Discov] 2017 Apr; Vol. 7 (4), pp. 400-409. Date of Electronic Publication: 2017 Feb 09.
Autor:
Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang HJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fujii T; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shelton DN; Bio-Rad Laboratories, Pleasanton, CA, USA.; Holden Comprehensive Cancer Center, University of Iowa Health Care, Iowa City, IA, USA., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zinner RG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cabrilo G; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kopetz ES; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Luthra R; Hematopathology, Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kee BK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Eng C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karlin-Neumann GA; Bio-Rad Laboratories, Pleasanton, CA, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Mar 01; Vol. 28 (3), pp. 642-650.